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Abstract. Alzheimer’s disease (AD) is the most prevalent form of neurodegenerative disorders characterized by neuritic plaques
containing amyloid- peptide (A) and neurofibrillary tangles. Evidence has been reported that A1-42 plays an essential
pathogenic role in decreased spine density, impairment of synaptic plasticity, and neuronal loss with disruption of memory-
related synapse function, all associated with AD. Experimentally, A1-42 oligomers perturb hippocampal long-term potentiation
(LTP), an electrophysiological correlate of learning and memory. A was also reported to perturb synaptic glutamate (Glu)-
recycling by inhibiting excitatory-amino-acid-transporters. Elevated level of extracellular Glu leads to activation of perisynaptic
receptors, including NR2B subunit containing NMDARs. These receptors were shown to induce impaired LTP and enhanced
long-term depression and proapoptotic pathways, all central features of AD. In the present study, we investigated the role of
Glu-recycling on A1-42-induced LTP deficit in the CA1. We found that A-induced LTP damage, which was mimicked by the
Glu-reuptake inhibitor TBOA, could be rescued by blocking the NR2B subunit of NMDA receptors. Furthermore, decreasing the
level of extracellular Glu using a Glu scavenger also restores TBOA or A induces LTP damage. Overall, these results suggest
that reducing ambient Glu in the brain can be protective against A-induced synaptic disruption.
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INTRODUCTION20
Amyloid- (A), a misfolded peptide, is widely21
regarded as a central player in the pathogenesis of22
Alzheimer’s disease (AD). The accumulation of sol-23
uble A [1] in the brain of patients and animal models24
of AD is associated with impairments of cognition25
and memory [2–4]. In addition, both the synthetic26
and brain-derived soluble A have been shown to27
damage certain forms of synaptic plasticity, corre-28
lates of learning and memory [5, 6]. Despite intense29
research, the mechanisms involved in A-mediated30
neuronal degeneration and dysfunction are not well31
understood.
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The hippocampus is especially affected in AD 32
including hippocampal-dependent cognitive abilities 33
such as learning and memory. Long-term potentiation 34
(LTP), a form of synaptic plasticity in the CA1 field 35
of the hippocampus, is impaired in animal models of 36
AD. Numerous studies reported that A1-42 oligomers 37
block hippocampal LTP ex vivo [7–9] and in vivo 38
[10, 11]. 39
Although the increased neuronal excitability caused 40
by A seems to contribute to and to be a key part 41
of the pathomechanism of AD, the exact mechanisms 42
by which neuronal over-activity develops is unknown. 43
Glutamate (Glu) excitotoxicity has been established 44
to have a major role in AD pathogenesis; however, 45
how A induces its effects is poorly understood. 46
Numerous findings confirmed that excitotoxic effects 47
of Glu contribute to progressive neuronal loss in AD 48
[12–14]. Inhibited excitatory-amino-acid-transporters 49
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(EAATs) may be a central player in this mechanism,50
and indeed, recent findings suggest that A oligomers51
perturb synaptic plasticity by altering Glu-recycling52
at the synapse [15, 16], resulting in elevated ambi-53
ent extracellular Glu-level in the brain [17, 18], which54
might be responsible for the overexcitation seen in55
AD. A blocks Glu-reuptake by inhibiting both neu-56
ronal and glial Glu transporters [16, 19], which might57
lead to extrasynaptic NMDAR (esyn NMDAR) acti-58
vation. Esyn NMDAR activation causes inhibited LTP59
[5], enhanced long-term depression (LTD) [20], and60
apoptosis [21].61
The aim of this study was to confirm that A causes62
synaptic Glu-spillover and esyn NMDAR activation,63
which leads to impaired synaptic plasticity in the64
CA1. We show that blocking Glu-reuptake with TBOA65
also impairs LTP, and both TBOA- and A-induced66
synaptic damage could be rescued by blocking NR2B67
subunit. Moreover, reducing the level of extracellu-68
lar Glu by applying a glutamate-scavenger enzyme69
GPT also provides protection against impaired synap-70
tic plasticity by TBOA and A.71
MATERIALS AND METHODS72
Compounds73
For the preparation of artificial cerebrospinal74
fluid (ACSF), all salts, glucose, sodium pyruva e75
(Pyr), glutamic-pyruvic transaminase (GPT),76
DL-threo--benzyloxyaspartate (TBOA), and -(4-77
Hydroxyphenyl)--methyl-4- benzyl-1-piperidinee-78
thanol (+)-tartrate salt (ifenprodil) were purchased79
from Sigma-Aldrich (St. Louis, MO). A1-42 was80
synthetized at the Department of Medical Chemistry81
University of Szeged, Hungary. Detailed description82
of the synthesis and characterization of A1-42 is83
reported in [7].84
Animals85
The study conformed to EU Directive 2010/63/EU86
and was approved by the regional Station for Ani-87
mal Health and Food Control under Project License88
XVI/8/2013. BALB/c mice were housed in groups of89
2-3 under standard conditions (24◦C, 12-h light-dark90
cycle) with food and water available ad libitum.91
Ex vivo electrophysiology92
Hippocampal slices of 400m in thickness were93
prepared from the brains of 3-month old mice using94
a standard protocol [22]. Briefly, slices were incu- 95
bated in ACSF gassed with 95% O2, 5% CO2 at 35◦C 96
for 60 min. ACSF was composed of (in mM) 130 97
NaCl, 3.5 KCl, 3 CaCl2, 1.5 MgSO4, 0.96 NaH2PO4, 98
24 NaHCO3, and 10 D-glucose, pH 7.4. Individual 99
slices were transferred to a 3D-MEA chip with 60 tip- 100
shaped and 60m high electrodes spaced by 200m 101
(Qwane Biosciences, Lausanne, Switzerland). The sur- 102
rounding solution was quickly removed, and the slice 103
was immobilized by placing a grid onto it. The slice 104
was continuously perfused with oxygenated ACSF 105
(3 ml/min at 36◦C) throughout the entire recording 106
session. Unfiltered data were recorded using a stan- 107
dard, commercially available MEA 60 setup (Multi 108
Channel Systems MCS GmbH, Reutlingen, Germany). 109
Field excitatory postsynaptic potentials (fEPSPs) were 110
recorded from the proximal stratum radiatum at 5 kHz. 111
Stimulation protocol 112
The Schaffer-collateral was stimulated by injecting 113
a biphasic voltage waveform (–100/+100s) through 114
one selected electrode at 0.033 Hz. Care was taken to 115
place the stimulating electrode in the same region at 116
every slice. The peak-to-peak amplitudes of fEPSPs at 117
the proximal stratum radiatum of CA1 were analyzed. 118
After a 30-min incubation period, the threshold and 119
maximum stimulation intensities for evoked responses 120
were determined. To evoke responses, 30% of the max- 121
imal stimulation intensity was used. LTP was evoked 122
by theta-burst stimulation (TBS). TBS comprised of 15 123
bursts given at 5 Hz and individual burst contained 4 124
pulses given at 100 Hz per burst. The level of LTP was 125
compared to the average of the last 10 peak-to-peak 126
amplitudes of evoked fEPSPs before TBS. 127
Drug treatments 128
After 10-min control level, slices were treated with 129
1M A1-42 or 5M TBOA for 60-min before LTP 130
was induced. Other cohort of slices was treated with 131
3M ifenprodil or 0.82 mM Pyr for 10-min then 2.06 132
U/ml GPT for 60-min before LTP induction. Separate 133
groups of slices were treated with these compounds 134
together with A1-42 or TBOA. 135
Statistics 136
Statistical significance was determined by using 137
ANOVA on ranks test with the post hoc Dunn’s method 138
(SigmaPlot 11 software package). The p value ≤0.05 139
was considered significant in all cases.
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RESULTS140
Aβ1-42-impaired LTP requires NR2B activation141
We recorded fEPSPs from the stratum radiatum of142
the CA1 using MEA electrodes. The peak-to-peak143
amplitudes of fEPSPs were analyzed from the proximal144
part of stratum radiatum.145
First, we verified the effect of A1-42 preparation146
on LTP in the hippocampal slices. Untreated slices147
showed a persistent elevated level of fEPSPs after148
LTP induction (168.33 ± 5.58%, n = 12), while A1-42149
reduced the magnitude of LTP (124.35 ± 4.88%, n = 9,150
p < 0.05, nonparametric ANOVA, Dunn post-hoc test;151
Fig. 1). Several recent studies suggested that differ-152
ent NR2 subunits of NMDARs may have divergent153
roles in NMDAR-dependent LTP activation and A154
pathology (see discussion). To test whether LTP acti-155
vation requires NR2B-containing NMDARs function, 156
slices were treated with an NR2B antagonist, ifen- 157
prodil. We observed that ifenprodil did not alter the 158
level of LTP compared to control (176.81 ± 4.93%, 159
n = 5), suggesting that NR2B-activation is not required 160
for LTP in the CA1. Furthermore, ifenprodil prevents 161
the A1-42 effect on LTP (166.03 ± 12.38%, n = 5, 162
p < 0.05, ANOVA on ranks, Dunn post-hoc test; Fig. 1), 163
suggesting A1-42 induce LTP damage is via NR2B- 164
containing NMDARs. None of the applied compounds 165
altered the amplitude of fEPSPs during the wash-in 166
period. 167
Glu-scavenger rescues the Aβ1-42-impaired LTP 168
To determine whether A1-42 affects Glu-reuptake, 169
we used an enzymatic Glu-scavenger system to 170
reduce extracellular Glu-levels. Slices were treated 171
Fig. 1. Blocking NR2B subunit prevents A1-42-induced LTP damage. Insets show representative fEPSPs before (black) and after treatment.
LTP was altered in A1-42 treated slices compared to untreated group (untreated versus A1-42: ∗p < 0.05; ANOVA on ranks, Dunn post-hoc
test). Ifenprodil did not change the level of LTP, however, it rescued the A1-42-impaired LTP. Error bars represent SEM; #p < 0.05 versus
A1-42.
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Fig. 2. Glu-scavenger restores A1-42-induced LTP damage. Insets show representative fEPSPs before (black) and after treatment. Pyr+GPT
treatment did not affect the level of LTP compared to untreated slices, however A1-42 induced LTP impairment was prevented by Glu-
scavenger (A1-42 versus Pyr+GPT+A1-42: #p < 0.05; ANOVA on ranks, Dunn post-hoc test). Error bars represent SEM; ∗p < 0.05 versus
untreated; #p < 0.05 versus A1-42.
with GPT and its substrate, Pyr for 10 min fol-172
lowed by A1-42 for 60 min, then LTP was induced.173
We have found that Pyr+GPT treatment does not174
affect the level of LTP compared to control slices175
(157.32 ± 6.68%, n = 5; Fig. 2). However, A1-42-176
induced LTP damage was prevented by Glu-scavenger177
(Pyr+GPT+A1-42: 159.66 ± 6.37%, n = 5 versus178
A1-42, p < 0.05, ANOVA on ranks, Dunn post-hoc179
test; Fig. 2).180
The effect of Aβ1-42 is mimicked by TBOA, a181
Glu-reuptake inhibitor182
TBOA was applied for 60 min before LTP induction.183
LTP was impaired by TBOA compared to untreated184
slice (123.22 ± 3.48%, n = 6, p < 0.05; ANOVA on185
ranks, Dunn post-hoc test, Fig. 3). Next, we tested186
whether NR2B subunit activation is required for187
the effect of TBOA. We have found that ifenprodil188
prevents TBOA-induced LTP damage suggesting 189
NR2B subunit activation is essential for the effect of 190
TBOA on LTP (ifenprodil+TBOA: 159.29 ± 10.67%, 191
n = 4 versus TBOA: p < 0.05; ANOVA on ranks, Dunn 192
post-hoc test, Fig. 3). We proceeded to apply Glu- 193
scavenger to test whether the inhibitory effect of TBOA 194
was due to the elevated extracellular Glu-level. Indeed, 195
TBOA-failed to impair LTP after Glu-scavenger treat- 196
ment (Pyr+GPT+TBOA: 169.28 ± 8.18, n = 5 versus 197
TBOA, p < 0.05; ANOVA on ranks, Dunn post-hoc 198
test, Fig. 4). Collectively these results suggest that 199
TBOA and A share common pathway in synaptotoxi- 200
city. The effect of A1-42 is mimicked by Glu-reuptake 201
inhibition; however both could be prevented by a Glu- 202
scavenger and NR2B inhibition suggesting that A1-42 203
disrupts synaptic plasticity by altering Glu-recycling 204
at the synapse in the CA1. Again, none of the applied 205
compounds altered fEPSP amplitude during the wash- 206
in period.
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Fig. 3. Ifenprodil prevents TBOA-impaired LTP. Insets show representative fEPSPs before (black) and after treatment. LTP was impaired by
TBOA compared to untreated group (untreated versus TBOA: ∗p < 0.05; ANOVA on ranks, Dunn post-hoc test), however TBOA-induced LTP
impairment was restored by ifenprodil (TBOA versus ifenprodil+TBOA: #p < 0.05; ANOVA on ranks, Dunn post-hoc test). Error bars represent
SEM; ∗p < 0.05 versus untreated; #p < 0.05 versus TBOA.
DISCUSSION207
There is growing evidence that soluble A208
oligomers mediate synaptic impairment in AD, but209
the exact mechanism of synaptotoxicity remains to be210
determined. Numerous studies have reported that A211
can affect the function of NMDARs [23–27], which212
may lead to excitotoxicity and neuronal hyperactiva-213
tion seen in the early stage of AD. Recent findings214
suggest that A binds to prion protein, metabotropic215
Glu receptor 5, and integrin receptors, and this com-216
plex initiates a molecular cascade mediated by fyn217
kinase [28–30], which subsequently phosphorylates218
NMDARs.219
An additional pathway of A-mediated hyperex-220
citation could be, however, that the concentration221
of extracellular Glu is increased by A. We have222
shown previously, that the excitatory effect of A, as223
was determined by the rate of spontaneous spiking 224
in hippocampal slices, is mediated by extrasynap- 225
tic NMDARs [22]. In the present study, we show 226
that A causes Glu spillover and subsequent esyn 227
NMDAR activation, which could be prevented by 228
either NR2B blockade or by “mopping-up” Glu with a 229
Glu-scavenger enzyme. 230
TBOA mimics the effects of Aβ 231
A has been shown to elevate extracellular Glu 232
concentration in the brain without altering gamma- 233
aminobutyric acid (GABA) level [18]. The mechanism 234
behind this is probably the inhibition of the trans- 235
porters mediating Glu-clearance. The level of brain 236
extracellular Glu is regulated by EAATs expressed 237
mainly on the astrocytes, which efficiently remove 238
the excess of this neurotransmitter from the synaptic 239
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Fig. 4. Glu-scavenger prevents TBOA-induced LTP damage. Insets show representative fEPSPs before (black) and after treatment. TBOA-
induced LTP impairment was restored by Glu-scavenger (TBOA versus Pyr+GPT+TBOA: #p < 0.05; ANOVA on ranks, Dunn post-hoc test).
Error bars represent SEM; ∗p < 0.05 versus untreated; #p < 0.05 versus TBOA.
cleft (reviewed by [31]). Indeed, A was shown to240
inhibit both glial and neuronal EAATs [16, 17, 32].241
Moreover, Noda and coworkers have reported that242
A may even cause reverse functioning of EAAT,243
leading to Glu-release from glial cells [33]. Further-244
more, down-regulation or abnormal expression and245
protein levels of EAAT1 and EAAT2 are altered in246
the hippocampus and frontal cortex of AD patients247
[34, 35] and in amyloid- protein precursor transgenic248
mice [32], further supporting that Glu-level regula-249
tion fails during AD pathomechanism. These effects250
may lead to Glu-spillover from the synapses and sub-251
sequent activation of esyn receptors. Of particular252
interest here, esyn NMDARs containing mainly NR2B253
subunit were shown to activate apoptotic pathways254
and promote synaptic depression [21]. In contrast,255
NR2A subunit-containing NMDARs localized mainly256
at the synaptic domain are antiapoptotic and participate257
in the induction of LTP in the CA1. We previ-258
ously reported that A1-42 induces hyperexcitability 259
via NR2B-containing NMDARs [22]. Indeed, block- 260
ing selectively NR2B subunits protected against A 261
effects (including LTP impairment), suggesting that 262
NR2B could be a promising target against AD [5, 263
8, 9, 36, 37]. Tackenberg et al. also suggest that 264
esyn NR2B-containing NMDARs activation is essen- 265
tial for tau-dependent neurodegeneration [26]. It was 266
also shown that the opposite form of synaptic plastic- 267
ity, LTD requires both syn and esyn receptor activation 268
[20], while LTP is not mediated by esyn NMDARs [8, 269
9]. It should be noted, however, that contradictory data 270
is available on the role of NR2B NMDARs on LTP: 271
esyn NDMARs are also recruited to the synapse dur- 272
ing LTP [38] and may play an essential role in LTP 273
maintenance [39, 40]. 274
Our results extend this line of research by showing 275
that reducing Glu that has been spilled-over from the 276
synapse with a Glu-scavenger enzyme also prevents 277
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A induced LTP impairment. Moreover, we show that278
blocking EAATs by a selective inhibitor, TBOA, mim-279
ics the effects of A: both compounds impair LTP, and280
this could be prevented by ifenprodil or GPT (Glu-281
scavenger).282
Reducing ambient Glu in the brain is protec-283
tive against A induced LTD enhancement [16]. A284
recent paper by Chen and Herrup makes the sugges-285
tion that although the level of glutamine-synthase is286
elevated in AD brains, its activity is severely com-287
promised by oxidative damage, leading to impaired288
Glu-metabolism [41].289
A and Glu-toxicity mediated dysfunction has been290
closely associated; however, decreasing the extracellu-291
lar Glu-level can be protective in other conditions such292
as brain ischemia [42], stroke [43], traumatic brain293
injury [44] or certain psychiatric disorders [45, 46].294
CONCLUSIONS295
Collectively, our results provide evidence that A296
impair Glu-recycling at the synapse, which leads to297
Glu-spillover and NR2B activation. Blocking NR2B or298
decreasing extracellular Glu offers protection against299
the synaptic plasticity impairment caused by A.300
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